Neurona Therapeutics

Neurona Therapeutics is gearing up for the Society for Neuroscience Annual 2024 Meeting, taking place from October 5th – 9th. Join our team on October 9th at 10:30 AM (CT) for a featured panel session. Marina Bershteyn, Ph.D., Director of Discovery Research, and Arturo Álvarez-Buylla, Ph.D., Professor of Neurological Surgery at UCSF, will present alongside Derek Southwell, MD, Ph.D., Assistant Professor of Neurosurgery at Duke University. The session, titled “Cortical Interneurons: From the Developing Brain to the Operating Room,” will dive into innovative approaches for interneuron transplantation as a potential therapy for epilepsy. Additionally, Geetha Subramanyam, Associate Scientist, will present a poster titled “Development of Functional Assays to Support the Characterization of MGE-Type Pallial GABAergic Inhibitory Cell Therapy for Drug-Resistant MTLE,” on October 6th from 8 AM to Noon (CT). It can be found under abstract number 9704. We’re excited to discuss our research with others in the industry!  #Neurona #Epilepsy #RegenerativeMedicine #Neuroscience2024

We’re pleased to announce that Neurona Therapeutics’ CEO, Cory Nicholas, will be participating in the 2024 William Blair’s Innovator Series and separately Leerink Partners Biopharma Private Company Connect event, both in the month of October.

Privileged to be able to offer this highly innovative experimental approach to our patients with drug resistant epilepsy. Thanks to Sandipan Pati, and the Texas comprehensive epilepsy program at McGovern Medical School, The University of Texas Health Science Center at Houston (UTHealth Houston) and Neurona Therapeutics. Thanks eapecially to Eli Klier and Jessica Johnson for all the heavy lifting and to our fantastic cell therapy core led by Fabio Triolo and Charles Cox

We’re happy to announce that Neurona Therapeutics will present a clinical update at the Epilepsy Foundation’s 2024 Pipeline Conference, taking place today and tomorrow at the Signia by Hilton in Atlanta, Georgia! John Hixson, M.D., Senior Medical Director, will give an oral presentation at 8:10 AM ET tomorrow, September 26. Additionally, Rose Larios, Ph.D., Clinical Research & Development Manager, will present a poster titled “First-in-Human Study of NRTX-1001 GABAergic Interneuron Cell Therapy for the Treatment of Focal Epilepsy” both days. We’re looking forward to sharing our latest advancements, so make sure to stop by if you’re attending the conference! #PipelineConference2024 #EpilepsyResearch #ClinicalTrials

We're #hiring a new Director, Program Management in South San Francisco, California. Apply today or share this post with your network.

We’re excited to announce that Cory Nicholas, PhD, Co-Founder and CEO of Neurona Therapeutics, will be a featured speaker at the upcoming ISSCR Copenhagen International Symposium in Copenhagen, Denmark. Join Dr. Nicholas at 2:45 PM CEST on October 2nd as he shares insights and developments regarding cell therapies for drug-resistant epilepsy.   The symposium, hosted by the International Society for Stem Cell Research, gathers leading scientists from around the world to explore the most exciting advancements in our field. Register to be a part of the conversation that shapes the future of stem cell research!   ISSCR Copenhagen International Symposium October 2-4 – Copenhagen, Denmark 🔗 https://lnkd.in/gWpry4um   #NeuronaTherapeutics #ISSCR2024 #StemCellResearch #RegenerativeMedicine #CopenhagenSymposium

As the fall semester begins, Neurona recognizes another successful summer internship program with undergrad students. We wish continued growth to our crew of future scientists as they blaze a path forward in school and in life! Brianna Xu Maureen M. Jose Vidal Sachita Chittal #Neurona #SummerInternship #InternshipProgram

Neurona Therapeutics is delighted to announce that it has been awarded a $3.8 Million CIRM grant for the development of a next generation neural cell therapy candidate. Today’s grant follows encouraging initial data from Neurona’s ongoing Phase1/2 clinical trial in adults with drug-resistant focal epilepsy. Read all about it here: https://lnkd.in/gEcrp6My.

What a fantastic way to close out the summer season! Our Neurona team had an unforgettable time at the Oracle Ballpark, celebrating the end of summer with an epic event that combined great company, thrilling baseball, and a whole lot of fun.   From the excitement of the game to the camaraderie of our colleagues, every moment was a reminder of the incredible team spirit and enthusiasm that drives us at Neurona. Whether it was cheering for home runs or enjoying delicious ballpark treats, the day was a perfect mix of relaxation and joy. A huge thank you to everyone who made this event special, and to our amazing team for their continued dedication and hard work. Here’s to more opportunities to come together and create unforgettable memories! #Neurona #TeamEvent #SummerFun #OracleBallpark #CompanyCulture #EndOfSummer

Our CEO, Cory R. Nicholas, PhD, was recently featured in a blog by the California Institute for Regenerative Medicine, in which he provided an update on the clinical development of NRTX-1001, our off-the-shelf neural cell therapy designed to treat drug-resistant focal epilepsy. The discussion highlighted the recent U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) designation for NRTX-1001, as well as the novel cell therapy's potential to treat epilepsy and other degenerative diseases like Alzheimer’s disease, and the implications for patients and the future of regenerative medicine. We are deeply grateful for CIRM’s ongoing support, which has been vital to our progress. Neurona remains committed to the vision of regenerative cell therapy that CIRM has championed.